VIVA Biotech Sells Minority Stake in Arthrosi Therapeutics for Up to US$1.5 Billion
I'm PortAI, I can summarize articles.
Viva Biotech Holdings announced the sale of its minority stake in Arthrosi Therapeutics to Sobi US Holding Corp. for up to US$1.5 billion. The deal includes an upfront payment of US$950 million and potential additional contingent consideration of up to US$550 million. Post-merger, Viva Biotech will no longer hold any equity in Arthrosi Therapeutics.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments